(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 December 2013 (12.12.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/182972 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *C07D 403/04* (2006.01)
A61K 31/4184 (2006.01) *C07D 417/14* (2006.01)
A61K 31/426 (2006.01) *A61P 25/00* (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:
PCT/IB2013/054567

(22) International Filing Date:
3 June 2013 (03.06.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12170748.3 4 June 2012 (04.06.2012) EP
13158520.0 11 March 2013 (11.03.2013) EP

(71) Applicant: **ACTELION PHARMACEUTICALS LTD** [CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).

(72) Inventors: **BOSS, Christoph**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **BROTSCHI, Christine**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **GUDE, Markus**; Grabenring 9, CH-4123 Allschwil (CH). **HEIDMANN, Bibia**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **SIFFERLEN, Thierry**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **WILLIAMS, Jodi, T.**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: BENZIMIDAZOLE-PROLINE DERIVATIVES



(I)

(57) Abstract: The present invention relates to compounds of the formula (I) wherein Ar^1, R^1, R^2, R^3, R^{4a}, R^{4b} and $(R^5)_n$ are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

WO 2013/182972 A1